Increased expression of SOX4 is associated with colorectal cancer progression

Wang, Baochun; Li, Yixiong; Tan, Fengbo; Zhanxiang, Xiao

doi:10.1007/s13277-015-4756-5

Cited by 34 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In CRC, SOX4 was upregulated at the mRNA and protein level, and was significantly associated with recurrence (29). SOX4 knockdown also inhibited the proliferation and invasion of CRC cells (29,30). Therefore, SOX4 may be a novel therapeutic target in CRC, due to its cancer-associated functions.…”

Section: Discussionmentioning

confidence: 99%

“…For example, inhibition of SOX4 represses prostate cancer proliferation, migration and invasion, and promotes the apoptotic process and the epithelial-mesenchymal transition in vitro (45). In CRC, SOX4 was upregulated at the mRNA and protein level, and was significantly associated with recurrence (29). SOX4 knockdown also inhibited the proliferation and invasion of CRC cells (29,30).…”

Section: Discussionmentioning

confidence: 99%

“…Among these putative targets, SOX4 was selected for further examination (Fig. 3A), as it is upregulated in CRC and is involved into CRC progression (29,30). A luciferase reporter assay was performed to determine whether miR-539 directly binds to the 3'-UTR of SOX4.…”

Section: Validation Of Sox4 As a Direct Target Of Mir-539 In Crcmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4

Zhao

Zhang

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Colorectal cancer (CRC) is the third most prevalent cancer and the fourth most common cause of cancer-associated mortality in males and females globally. Aberrant expression of microRNA-539 (miR-539) has been reported in multiple types of cancer. However, miR-539 expression, function and underlying mechanisms have not been clearly elucidated in CRC. In the present study, miR-539 expression was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in CRC tissues and cell lines. The effects of miR-539 on CRC cells were further examined in in vitro studies. In addition, the direct targets of miR-539 in CRC were investigated using bioinformatics, luciferase reporter assays, RT-qPCR and western blotting. miR-539 was revealed to be significantly downregulated in CRC cell lines and tissues. Decreased miR-539 expression was associated with lymph node metastasis and tumor-node-metastasis stage in patients with CRC. Functional assays revealed that the rescue of miR-539 expression attenuated CRC cell proliferation and invasion in vitro. Additionally, SRY-box 4 (SOX4) was validated as a direct target gene of miR-539 in CRC. Furthermore, SOX4 was revealed to be upregulated in CRC tissues at the mRNA and protein level. A significant negative correlation between miR-539 and SOX4 mRNA expression levels was observed in CRC tissues. Furthermore, upregulation of SOX4 partially restored the tumor suppressive effects of miR-539 on CRC cell proliferation and invasion. Taken together, this suggests that miR-539 may serve tumor-suppressive functions in CRC during the process of malignant transformation, by directly targeting SOX4. miR-539/SOX4-based targeted therapy may represent a potential novel treatment for patients with CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4

Zhao

Zhang

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…SOX4, a member of the SOX family (37), was observed to be a direct and functional target of miR-339-5p in AML in the present study. Increasing evidence suggests that SOX4 is aberrantly and highly expressed in numerous types of human cancers, including gastric cancer (38), hepatocellular carcinoma (39), colorectal cancer (40), osteosarcoma (41) and cervical cancer (42). SOX4 serves oncogenic roles in the onset and development of tumours by affecting cell proliferation, apoptosis, the cell cycle, migration and metastasis (43)(44)(45).…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑339‑5p inhibits cell proliferation of acute myeloid leukaemia by directly targeting SOX4

Sun

Liu

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

In recent decades, microRNAs (miRNAs) have been considered novel gene regulators. Dysregulated miRNAs serve crucial roles in the formation and progression of acute myeloid leukaemia (AML). Therefore, the roles of differentially expressed miRNAs in AML require extensive investigation to obtain insight into the treatment of patients with AML. The present study demonstrated significant miR-339-5p downregulation in AML samples and cell lines. miR-339-5p overexpression attenuated AML cell proliferation by inducing cell cycle arrest and promoting cell apoptosis. Additionally, sex-determining region Y-related high-mobility group box 4 (SOX4) was identified as a direct target gene of miR-339-5p in AML. Furthermore, SOX4 expression was significantly upregulated in AML samples; this upregulation was inversely correlated with the expression levels of miR-339-5p. Additionally, a series of rescue experiments demonstrated that SOX4 resumption reversed the effects of miR-339-5p overexpression on cell proliferation, cycle status and apoptosis of AML. In conclusion, miR-339-5p may serve its antiproliferative role in AML by directly targeting SOX4, which suggests that miR-339-5p may be considered an effective novel therapeutic target for treating patients with such an aggressive haematological malignancy.

show abstract

“…17 Recently, the overexpression of SOX4 has been reported in several tumors, including prostate cancer, breast cancer and colon cancer. [18][19][20] It has well documented that SOX4 stabilizes b-catenin, and increases Wnt signaling pathway in many types of cancers. 21 Taking together it seems that SOX4 transcription factor plays an vital role in Wnt signaling pathways in TNBC 14,22 Aberrant Fzd7 expression is found in different types of human cancers.…”

Section: Introductionmentioning

confidence: 99%

Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor

et al. 2017

View full text Add to dashboard Cite

ABSTACTWnt/b-catenin signaling pathway through Frizzled receptors has been shown to play a key role in both normal development and tumorigenesis. Overexpression of Wnt pathway genes, such as Fzd7 in several malignancies is well-documented. Therefore, targeting of Fzd7 and its ligand inhibits cancer cells proliferation metastasis. In the present study we isolated single chain variable fragments (scFvs) against Fzd7 receptor using phage display method. Semi-synthetic human naive antibody libraries (Tomlinson I C J) was employed in panning procedure to isolate specific scFv against specific peptide from extracellular domain of Fzd7 receptor. The reactivity and growth inhibition effects of the selected antibodies was evaluated using enzyme-linked immunosorbent assay (ELISA), MTT and annexin V assays, respectively. Seven scFvs reactive to Fzd7 were selected following 4 rounds of panning. The results showed that the selected scFvs inhibits cell growth through apoptosis cell death in a triple negative breast cancer cells, MDA-MB-231. Given that Fzd7 and Wnt pathway plays a critical role in tumor progression, selected blocking scFvs represent significant potential for immunotherapy of breast cancer cells.

show abstract

Increased expression of SOX4 is associated with colorectal cancer progression

Cited by 34 publications

References 23 publications

MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4

MicroRNA‑539 inhibits colorectal cancer progression by directly targeting SOX4

MicroRNA‑339‑5p inhibits cell proliferation of acute myeloid leukaemia by directly targeting SOX4

Developing and characterization of single chain variable fragment (scFv) antibody against frizzled 7 (Fzd7) receptor

Contact Info

Product

Resources

About